PMID- 23838134
OWN - NLM
STAT- MEDLINE
DCOM- 20140130
LR  - 20151119
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 13
IP  - 2
DP  - 2013
TI  - Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in 
      colorectal cancer patients.
PG  - 67-73
LID - 10.3233/CBM-130345 [doi]
AB  - OBJECTIVE: To determine the usefulness of brain-derived neurotrophic factor 
      (BDNF) as a diagnostic biomarker for colorectal cancer (CRC). MATERIALS AND 
      METHODS: ELISA immunoassay was used to examine BDNF concentrations in the sera of 
      two different retrospective cohorts consisting of CRC patients and age/gender 
      matched controls. Cohort 1 consisted of 99 controls and 97 CRC patients, whereas 
      cohort 2 consisted of 47 controls and 91 CRC patients. RESULTS: In cohort 1, the 
      median concentration of BDNF was significantly (p< 0.0001) lower in CRC patient 
      samples (18.8 ng/mL, range 4.0-56.5 ng/mL) than control samples (23.4 ng/mL, 
      range 3.0-43.1 ng/mL). This finding was validated in an independent patient 
      cohort (CRC patients: 23.0 ng/mL, range 6.0-45.9 ng/mL; control patients: 32.3 
      ng/mL, range 14.2-62.4 ng/mL). BDNF concentrations did not differ significantly 
      between Dukes' staging in the patient cohort, however patients with Stages A, B, 
      C and D (p< 0.01 for each stage) tumours had significantly reduced BDNF levels 
      compared to healthy controls. Receiver operating characteristic analysis was 
      performed to determine the ability of BDNF to discriminate between healthy 
      controls and those with CRC. At 95% specificity, BDNF concentrations 
      distinguished CRC patients with 25% and 18% sensitivity, respectively, in cohorts 
      1 and 2 (cohort 1: AUC=0.79, 95% CI 0.70-0.87; cohort 2: AUC =0.69, 95% CI 
      0.61-0.76). CONCLUSION: The serum levels of BDNF were significantly lower in 
      colorectal cancer patients when compared to a control population, and this did 
      not differ between different Dukes' stages.
FAU - Brierley, G V
AU  - Brierley GV
AD  - CSIRO Preventative Health National Research Flagship, Adelaide BC, South 
      Australia, Australia.
FAU - Priebe, I K
AU  - Priebe IK
FAU - Purins, L
AU  - Purins L
FAU - Fung, K Y C
AU  - Fung KY
FAU - Tabor, B
AU  - Tabor B
FAU - Lockett, T
AU  - Lockett T
FAU - Nice, E
AU  - Nice E
FAU - Gibbs, P
AU  - Gibbs P
FAU - Tie, J
AU  - Tie J
FAU - McMurrick, P
AU  - McMurrick P
FAU - Moore, J
AU  - Moore J
FAU - Ruszkiewicz, A
AU  - Ruszkiewicz A
FAU - Burgess, A
AU  - Burgess A
FAU - Cosgrove, L J
AU  - Cosgrove LJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Carcinoembryonic Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Carcinoembryonic Antigen/blood
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/*blood/diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
EDAT- 2013/07/11 06:00
MHDA- 2014/01/31 06:00
CRDT- 2013/07/11 06:00
PHST- 2013/07/11 06:00 [entrez]
PHST- 2013/07/11 06:00 [pubmed]
PHST- 2014/01/31 06:00 [medline]
AID - A35302512761NQ1U [pii]
AID - 10.3233/CBM-130345 [doi]
PST - ppublish
SO  - Cancer Biomark. 2013;13(2):67-73. doi: 10.3233/CBM-130345.